MedTrace Logo

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2012-11-30

No results posted yet for this study

Summary

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 6 mg/mL

Administered as an injection into an anterior juxtascleral depot

DRUG

Anecortave Acetate Sterile Suspension, 3.75 mg/mL

Administered as an injection into an anterior juxtascleral depot

DRUG

Anecortave Acetate Sterile Suspension, 96 mg/mL

Administered as an injection into an anterior juxtascleral depot

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/ML

Administered as an injection into an anterior juxtascleral depot

OTHER

Anecortave Acetate Vehicle

Administered as an injection into an anterior juxtascleral depot

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788541 on ClinicalTrials.gov